Clinical Trials

Multiple clinical trials with completed recruitment status have evaluated interventions for aesthetic and structural cutaneous concerns, specifically skin aging, wrinkles, and cheek line depressions. Sponsored by corporate and contract research entities including Allergan, Amazentis SA, and proDERM GmbH, these completed studies encompass both Phase 4 evaluations and non-phased trial designs.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05805735 Completed
Aging|Wrinkle
Amazentis SA|proDERM GmbH
2023-03-28 Not Applicable
NCT02980783 Completed
Cheek Line Depressions
Allergan
2016-10-13 Phase 4

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Prednicarbate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a medium-potency corticosteroid, prednicarbate binds to intracellular glucocorticoid receptors, inhibiting pro-inflammatory transcription factors and suppressing downstream cytokine synthesis to limit local immune cell activation. This targeted repression of inflammatory signaling reduces cellular stress and vascular permeability, mitigating dermal tissue changes associated with clinical conditions such as skin aging, wrinkles, and cheek line depressions.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.